Company aims to make revolutionary treatment readily accessible with $7-million private placement offering
DealSquare, a private-investment platform that utilizes NEO technology, has secured another listing with the addition of a Calgary-based company that’s offering a revolutionary treatment for pain and mental-health issues.
Doctor’s Ketamine and Wellness has launched a $7-million private-placement offering on the DealSquare platform. To help curb mental-health and chronic pain disorders affecting billions around the world, the company said it is aiming to be “the premier global provider of outpatient ketamine and vitamin hydration infusions” as part of the $4.5-trillion global wellness economy.
The company is planning to commercialize treatment based on research done by Dr. Christopher Romig, Senior Medical Director at Doctor’s Ketamine, who is also said to have done pioneering work in ketamine infusion therapies in Orange County, California. Ketamine infusions, the company said, are known to provide relief for depression, chronic pain, anxiety, and PTSD in a matter of hours or days, compared to the four- to six-week timeframe required for most antidepressants.
With the proceeds from the DealSquare prive placement, Doctor’s Ketamine said it will seek to establish an international network of clinics to offer intravenous ketamine infusions, to be complemented by a selection of customized vitamin and nutraceutical hydration infusions. Its initial plans are to open and operate clinics strategically located in the U.S., Canada, and the U.K., followed by expansion throughout Europe in the long term.
“Close to 2 billion people around the world suffer from mental health and pain disorders,” said Doctor’s Ketamine & Wellness CEO Michael Hale. “Ketamine therapies have the potential to help resolve this silent, global crisis and give people new hope for a better life.”
Hale said that by launching on DealSquare, the company expects to get the exposure needed to scale up operations and expand its range of services with first-mover advantage in under-serviced markets.
“The Global Wellness Economy is a multitrillion dollar industry, growing rapidly and attracting investments from larger professional and institutional investors,” said DealSquare Managing Director Peter-Paul Van Hoeken. “The listing of Doctor’s Ketamine & Wellness on DealSquare opens up this investment opportunity to the wider investor community.”
“The proprietary ketamine treatments developed by the Doctor’s Ketamine team have proven to be remarkably effective in treating some of the world’s most pressing mental health issues,” said NEO President and CEO Jos Schmitt. “Like DealSquare and NEO, they are challenging the status quo and are bringing great hope to the market.”
